Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to...
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with...
Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19. #COVID19 #SARScov2 #coronavirus

Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19.

Feature | Coronavirus (COVID-19) | March 24, 2020 | Marianne Pop, Pharm.D, BCPS
It has been more than three months since the word coronavirus was uttered on everyone’s lips and all over the social...
The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. 
Feature | Pharmaceuticals | February 24, 2020
February 24, 2020 — The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet,...
Videos | Antiplatelet and Anticoagulation Therapies | February 18, 2020
Carey Kimmelstiel, M.D., FACP, FACC, director, interventional cardiology, director, cardiac catheterization lab, Tufts...
The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib). 
News | Left Atrial Appendage (LAA) Occluders | February 03, 2020
February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess...
Indications expanded for Ozempic and Rybelsus to reduce cardiovascular risk in adults with type 2 diabetes and known heart disease
News | Pharmaceuticals | January 29, 2020
January 29, 2020 - The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk's Ozempic...
This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals | January 09, 2020
January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies, a...
The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) from AstraZeneca and granted priority review for dapagliflozin (Farxiga) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).
News | January 07, 2020
January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA)...
 Christie Ballantyne

Dr. Christie Ballantyne, professor of medicine and chief of the section of cardiology at Baylor College of Medicine

News | Pharmaceuticals | December 30, 2019
December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained and...
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of...
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | December 16, 2019 | Dave Fornell, Editor
December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent...
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have...
Heart failure VICTORIA TrIal a success. Dave Fornell
News | Heart Failure | November 21, 2019
November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of...